Niacin, also known as vitamin B3, has a surprisingly complex relationship with the kidneys. It can protect kidney cells from acute injury by replenishing a critical energy molecule called NAD+, help manage dangerously high phosphorus levels in people on dialysis, and improve cholesterol profiles in chronic kidney disease. At the same time, certain niacin breakdown products accumulate when kidneys fail and may contribute to cardiovascular risk. The picture is not one of straightforward benefit or harm, and the details matter for anyone with kidney concerns or their clinicians.
Why NAD+ Matters to Kidney Cells
To understand niacin’s role in kidney health, you need to know about NAD+, a molecule your cells require to produce energy. Kidneys are energy-hungry organs. The tubular cells that do most of the work of filtering blood and reclaiming useful molecules rely heavily on mitochondria, and those mitochondria depend on NAD+ to keep functioning. When something damages the kidney, whether reduced blood flow during surgery, a toxic drug, or a crush injury, NAD+ levels in kidney tissue drop sharply. That energy crisis is a central driver of cell death in acute kidney injury.
Niacin and its close relative nicotinamide are precursors the body uses to make NAD+. The idea behind niacin-based kidney therapies is straightforward: if falling NAD+ levels contribute to kidney damage, then boosting NAD+ back up should help cells survive the insult. Animal studies have consistently supported this logic, and early human trials are now testing whether it holds up in patients.
Protection Against Acute Kidney Injury
Acute kidney injury, or AKI, is a sudden loss of kidney function that can happen after major surgery, severe infection, or exposure to certain drugs. It is common in hospitalized patients and carries real risks of lasting kidney damage. The evidence that boosting NAD+ can soften the blow of AKI comes primarily from animal experiments, but the results have been encouraging enough to move the concept toward clinical trials.
In mouse models of ischemia-reperfusion injury, where blood flow to the kidney is temporarily cut off and then restored, nicotinamide given before or shortly after the injury reduced creatinine levels, a standard marker of kidney dysfunction. One set of experiments showed that nicotinamide brought creatinine down from roughly 1.9 to 1.1 mg/dL in normal mice and from about 2.6 to 1.5 mg/dL in mice genetically predisposed to more severe injury. Similar benefits appeared in cisplatin-induced kidney damage, a model for the nephrotoxicity that chemotherapy patients sometimes face.1PubMed Central. The tryptophan pathway and nicotinamide supplementation in ischaemic acute kidney injury
A related compound called NMN, which the body converts into NAD+, has shown protection in models of heme protein-induced AKI, the type of kidney injury caused by the release of myoglobin from damaged muscle tissue. In those experiments, NMN preserved NAD+ levels in kidney tissue and led to less tubular necrosis, reduced cell death, better-preserved mitochondrial structure, and lower expression of injury markers.2PubMed Central. NAD+-Boosting Ameliorates Heme Protein–Mediated Acute Kidney Injury A separate experimental approach used NAD+ loaded into nanoparticles and delivered directly to mouse kidneys or intravenously. Both delivery routes significantly reduced creatinine levels and tubular injury scores compared with controls.3Transplantation Direct. Attenuating Ischemia and Reperfusion Injury Using NAD(+)-Loaded Nanoparticles in Mouse Kidneys
The consistency across different injury models and different NAD+ precursors is what makes this area of research compelling. Whether the trigger is low blood flow, a toxic drug, or muscle breakdown, the underlying energy deficit in kidney cells responds to NAD+ replenishment. The key caveat is that almost all of this evidence is from animal studies, and treatments that work well in mice do not always translate to humans at the same doses or timing.
Managing Phosphorus in Chronic Kidney Disease
When kidneys lose their ability to filter properly, phosphorus builds up in the blood. This is a serious problem for people with advanced chronic kidney disease and especially those on dialysis. Elevated phosphorus drives calcium deposits in blood vessels, weakens bones, and is linked to a higher risk of death in dialysis patients. Standard treatment involves phosphate binder pills taken with meals, but many patients struggle to keep their levels controlled even with binders, partly because the pill burden is already high and adherence drops off.
Niacin and nicotinamide work differently from phosphate binders. Instead of binding phosphorus in the gut after it has been consumed, they reduce the intestinal absorption of phosphorus in the first place by downregulating a sodium-phosphate transporter in the gut wall.4PubMed Central. Nicotinamide and phosphate homeostasis in chronic kidney disease This makes them an appealing add-on therapy, potentially allowing patients to use fewer binder pills while achieving better phosphorus control.
Clinical trials in dialysis patients have confirmed that niacin can lower serum phosphorus. In one trial, eight weeks of niacin treatment reduced phosphorus levels from an average of about 6.7 mg/dL down to about 6.0 mg/dL, a statistically meaningful drop. That may sound modest, but in the context of dialysis, where phosphorus levels are stubbornly hard to move, any reliable reduction matters. The main barrier in that trial was flushing: roughly 40% of patients experienced mild to moderate skin flushing, and a handful had to stop the drug because of it.5PubMed Central. The effect of niacin on serum phosphorus levels in dialysis patients
Flushing is niacin’s most notorious side effect. It involves a warm, sometimes itchy reddening of the face and upper body that typically begins within 30 minutes of taking a dose. Extended-release formulations and nicotinamide, the amide form of vitamin B3, cause less flushing than immediate-release niacin. This difference matters clinically because kidney patients already face a demanding regimen of medications, and adding a drug that makes you feel uncomfortably hot several times a day is a hard sell.
Cholesterol and Triglycerides in Kidney Patients
People with chronic kidney disease often develop a characteristic pattern of abnormal blood fats: low HDL (“good”) cholesterol, elevated triglycerides, and sometimes high LDL. This dyslipidemia contributes to the extremely high cardiovascular death rate seen in kidney disease patients. Niacin is one of the most effective drugs at raising HDL cholesterol, and it also lowers triglycerides and total cholesterol.6PubMed. Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials
In a study of kidney disease patients given low-dose niacin over 24 weeks, HDL cholesterol rose significantly and triglycerides fell significantly compared with baseline. The improvements appeared as early as 12 weeks and held through the end of the study.7PubMed Central. Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease A larger post-hoc analysis from the AIM-HIGH trial, which included participants with chronic kidney disease, found that extended-release niacin reduced triglycerides by a median of 59 mg/dL and raised HDL by an average of about 11 mg/dL over three years of follow-up.8PubMed Central. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial
These lipid improvements look promising on paper, but whether they actually translate into fewer heart attacks and strokes in kidney patients remains an open question. The broader AIM-HIGH trial itself was stopped early because adding niacin to statin therapy did not reduce cardiovascular events in the overall study population. That result cast a long shadow over niacin’s reputation as a cardiovascular drug, and the kidney-specific findings have to be interpreted with that disappointment in mind. The lipid numbers improve, but the harder endpoint of fewer heart attacks has not been clearly demonstrated in this population.
A Darker Side of Niacin Metabolism
Here is where the story takes a turn that caught many researchers off guard. When your body processes niacin, it eventually produces breakdown products including two compounds abbreviated 2PY and 4PY. In people with healthy kidneys, these metabolites are cleared efficiently in urine. But when kidney function declines, they accumulate in the blood.
A 2024 study published in Nature Medicine found that elevated levels of 4PY were significantly associated with the risk of major cardiovascular events, and this association held regardless of kidney function. Elevated 2PY, on the other hand, was only associated with cardiovascular risk in people who already had impaired kidney function, with a highly significant interaction between 2PY levels and kidney function status.9PubMed Central. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk The researchers provided evidence that 4PY can promote vascular inflammation, suggesting a mechanism by which excess niacin metabolism could actually contribute to the cardiovascular disease it was once hoped to prevent.
This finding complicates the calculus around niacin supplementation in kidney patients. If you have reduced kidney function, you clear these metabolites less effectively, meaning they build up to higher concentrations. Earlier work had already identified 2PY as a candidate uremic toxin, a substance that accumulates in kidney failure and contributes to the syndrome of illness that dialysis patients experience.10PubMed. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Hemodialysis does bring 2PY levels down, but concentrations rebound within about 48 hours after a session, meaning the toxin exposure is chronic rather than brief.11PubMed. Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure
The tension here is real. On one hand, niacin lowers phosphorus and improves lipid profiles in kidney disease. On the other, its metabolic byproducts may contribute to the cardiovascular toxicity that kills more kidney patients than kidney failure itself. The research community has not resolved this yet, and it is one reason that niacin has not become a standard part of CKD management despite decades of interest.
Diabetic Kidney Disease and Fibrosis
Diabetes is the leading cause of chronic kidney disease worldwide, and the kidney damage it produces involves a distinctive mix of inflammation, oxidative stress, and progressive scarring known as fibrosis. These processes gradually destroy the kidney’s filtering architecture and are the main reason diabetic kidney disease progresses toward dialysis.
Nicotinamide has shown protective effects in animal models of diabetic kidney disease. In one study using diabetic mice, treatment with nicotinamide reduced renal fibrosis, inflammation, and oxidative stress compared with untreated diabetic controls. The protective mechanism appeared to involve activation of Sirt1, a protein that regulates cellular stress responses and is itself dependent on NAD+ levels.12PubMed Central. Nicotinamide protects against diabetic kidney disease through regulation of Sirt1 This creates a coherent biological story: niacin feeds NAD+ production, NAD+ activates Sirt1, and Sirt1 dials down the inflammatory and fibrotic pathways that drive diabetic kidney damage.
The challenge, again, is moving from mice to people. Diabetic kidney disease in humans develops over years to decades, and the doses and duration of nicotinamide treatment that would be needed to meaningfully slow fibrosis in patients remain unknown. The metabolite accumulation concern described above applies doubly here, since patients with diabetic kidney disease often have exactly the impaired clearance that allows 2PY and 4PY to build up.
Niacin Deficiency in Dialysis Patients
While much of the research focuses on giving extra niacin to kidney patients, the opposite problem also exists. People on long-term hemodialysis are at risk of niacin deficiency, partly because dialysis removes water-soluble vitamins from the blood and partly because appetite and dietary intake often decline as kidney disease worsens. Severe niacin deficiency causes pellagra, characterized by the classic triad of dermatitis, diarrhea, and cognitive changes. Case reports describe pellagra occurring in hemodialysis patients, particularly those with additional risk factors like cancer or poor nutritional status.13PubMed. Pellagra Disease in a Hemodialysis Patient
This creates a paradox that is worth recognizing. A dialysis patient might simultaneously have too little niacin in their diet and too much of niacin’s toxic metabolites in their blood. The metabolites accumulate because the kidney cannot clear them, not because dietary niacin intake is high. Addressing the deficiency with modest supplementation is a different clinical question from using pharmacological doses of niacin to manage phosphorus or lipids. Most nephrologists recommend water-soluble vitamin supplements for dialysis patients that include small amounts of B vitamins, but the optimal dose of niacin specifically for this population is not well established.
Hartnup Disease and Tryptophan Handling
Niacin has a genetic connection to kidney function that most people never encounter. Hartnup disease is a rare inherited condition in which the transport system for neutral amino acids in the gut and kidney tubules is defective. One of those amino acids is tryptophan, which the body normally uses to synthesize niacin internally. In Hartnup disease, tryptophan is poorly absorbed from food and simultaneously lost in large amounts through the urine because the kidney tubules cannot reclaim it.14Indian Journal of Dermatology. Hartnup Disease
The result is a functional niacin deficiency even when dietary niacin intake is adequate, because the body’s ability to make its own niacin from tryptophan is compromised. The symptoms resemble pellagra and can include a photosensitive rash, neurological problems, and diarrhea. Treatment is straightforward: niacin supplementation bypasses the tryptophan absorption problem entirely. Hartnup disease is rare enough that most doctors never see a case, but it illustrates an important principle: kidney tubular function and niacin status are directly linked, because the kidney is one of the two sites (along with the gut) where amino acid absorption determines how much raw material the body has to make its own B3.
Transplant Research and Nanoparticle Delivery
Kidney transplantation involves an unavoidable period of ischemia-reperfusion injury. The donor kidney is removed, cooled, transported, and then reconnected to a blood supply in the recipient. That period without blood flow depletes NAD+ in the organ’s cells, and the rush of oxygen when blood flow returns triggers a burst of damaging free radicals. The extent of this injury affects how quickly the transplanted kidney starts working and can influence long-term graft survival.
Researchers have begun exploring whether delivering NAD+ directly to transplant kidneys could reduce this damage. The nanoparticle study mentioned earlier found that loading NAD+ into tiny particles and either injecting them into the kidney or delivering them intravenously significantly reduced both creatinine levels and tissue injury scores in a mouse model of ischemia-reperfusion.3Transplantation Direct. Attenuating Ischemia and Reperfusion Injury Using NAD(+)-Loaded Nanoparticles in Mouse Kidneys The nanoparticle approach is interesting because it concentrates the NAD+ where it is needed rather than flooding the entire body, potentially avoiding the metabolite accumulation concerns that apply to systemic niacin dosing.
This kind of targeted delivery is still in early-stage research, but it represents a different philosophy from giving a patient niacin pills. Rather than relying on the body to convert dietary niacin through several enzymatic steps into NAD+, you supply the finished product directly to the organ at the moment of greatest need. If the approach works in larger animal models and eventually in human transplants, it could become part of organ preservation protocols alongside the cold storage solutions currently used.
Practical Considerations and Open Questions
If you have kidney disease and are wondering whether you should take niacin supplements, the honest answer is that the evidence does not yet support routine self-supplementation. The phosphorus-lowering and lipid-improving effects are real but modest, and they have not been shown to reduce hard outcomes like death or dialysis need. Meanwhile, the metabolite accumulation concern is genuine and not fully characterized. The research community is still working out where the balance tips.
Several practical points are worth knowing. First, niacin comes in multiple forms with different side-effect profiles. Immediate-release niacin causes the most flushing, extended-release formulations cause less, and nicotinamide causes the least. But nicotinamide does not have the same lipid-modifying effects as niacin, so the form matters depending on the therapeutic goal. Second, over-the-counter “no-flush niacin” products often contain inositol hexanicotinate, a compound that releases niacin poorly and may not deliver meaningful blood levels of the active vitamin at all. These products should not be assumed to have the same effects as the formulations used in clinical trials.
Third, if you are on dialysis, your nephrologist likely already has you on a water-soluble vitamin supplement that includes a small dose of niacin. This is appropriate and different from the pharmacological doses used in the phosphorus and lipid studies, which typically start around 500 mg per day and go higher. The gap between a nutritional dose and a therapeutic dose is large, and the risks differ accordingly. Anyone considering high-dose niacin for kidney-related reasons should do so under medical supervision, with monitoring of phosphorus, lipids, liver function, and blood glucose, since niacin can worsen insulin resistance at higher doses.
The field is watching several ongoing and planned trials that may clarify niacin’s role. The NAD+ boosting strategy for AKI prevention is being tested in patients undergoing cardiac surgery, a setting where AKI is common and the timing of the insult is predictable. If oral nicotinamide given before surgery can reduce post-operative kidney injury in humans the way it does in mice, that would be a meaningful advance in a condition that currently has no specific preventive therapy.